Table 1 Patient baseline characteristics
Characteristic | n = 16 |
|---|---|
Age, median (range. yrs) | 68.6 (56.7 – 82.6) |
Sex, female/male (%) | 5/11 (31/69) |
R-ISS disease stage, n (%) | |
I | 6 (38) |
II | 7 (44) |
III | 3 (19) |
Cytogenetik alterations, n (%) | |
High risk | 6 (38) |
del(17p) | 4 (25) |
t(4;14) | 2 (13) |
t(14;16) | 0 (0) |
Standard risk | 9 (56) |
Unknown | 1 (6) |
Time from initial MM diagnosis to treatment with ide-cel, median (range, yrs) | 7.7 (2.1–16.7) |
Previous anti-myeloma regimens, median (range) | 6 (3–12) |
Previous ASCT, median (range) | 1.5 (1–4) |
Patients with Allo-SCT, n (%) | 1 (6) |
ECOG status, n (%) | |
0 | 11 (69) |
1 | 4 (25) |
2 | 1 (6) |
High tumor burden, n (%) | 5 (31) |
Elevated serum ferritin, n (%) | 9 (56) |
High D-Dimers, n (%) | 9 (56) |
Extramedullary disease, n (%) | 5 (31) |